Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea

Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Jaemin, Kim, Jung Ho, Kim, Ji Young, Hyun, Changlim, Rhee, Jiyoung, Kwon, Jungmi, Han, Sanghoon, Kim, Wookun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720062/
https://www.ncbi.nlm.nih.gov/pubmed/25715772
http://dx.doi.org/10.4143/crt.2014.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720062/
https://www.ncbi.nlm.nih.gov/pubmed/25715772
http://dx.doi.org/10.4143/crt.2014.209

Ejemplares similares